-
Mosquito-borne diseases
- malaria
- dengue
- yellow fever
- chikungunya fever
- filariasis
- several forms of encephalitis
- dog heartworm
-
Mosquito anatomy and feeding
- female's mouthparts form piercing proboscis
- both genders usually feed on nectar, but females also take blood meals - female injects saliva into host as anticoagulant
-
mosquito life cycle
- females lay eggs on the surface of water
- hatch into larvae, turn into pupae
- pupae live at surface water and then become adults
- females can live longer
-
prevention of mosquito-borne diseases
- avoidance of outdoor activity during dawn and dusk
- limit area of exposed skin by wearing more covering clothing
- used bed nets if accommodations are not properly screened
- mosquito repellants applied to clothing, tents, skin and other gear
- elimination of water breeding sources
- mosquito control campaigns (DDT spraying)
-
Malaria background
- probably transferred to humans from chimpanzees or other apes
- beginnings of agriculture and civilization caused impingement into apes habitat
- deforestation lead to increased standing water
- first noted in 4th century
-
Malaria etiology
- Genus: Plasmodium
- Species:
- P. falciparum - most common in Africa, causes the most severe illness, drug resistant, has different diagnostic characteristics
- P. vivax - most common species in the world, causes relapse, latent phase in liver
- P. ovale - rare, causes relapse, latent phase in liver
- P. malariae - rare, asexual cycle is 72 hours
-
Malaria worldwide occurrence
- top infectious cause of death of humans throughout history
- leading cause of death among children under 5 in sub-Saharan Africa
-
HIV and Malaria
- increased incidence of malaria infection in HIV infected adults - weakened immune system allows for increased parasite load
- HIV infected adults have more febrile episodes - more attractive to mosquitoes
- treatment and prevention for both must be well coordinated
-
Malaria transmission
mosquitoes - bite of female Anopheles mosquito, inoculation of infected blood
-
Malaria temporal pattern
incidence peaks when mosquito levels peak
-
Malaria human stages
- sporozoites inoculated into human host from mosquito
- sporozoites infect liver cells (heptacytes)
- mature into schizonts
- rupture and release merozoites - infect red blood cells (erythrocytes)
- some parasites differentiate into sexual erthyrocytic stages called gametocytes
-
Malaria mosquito stages
- gametocytes are ingested by Anopheles mosquito
- microgametes penetrate macrogametes and form zygotes in mosquito's stomach
- zygotes become motile and elongated, mature into ookinetes
- these invade midgut wall and develop into oocysts
- oocysts rupture and release sporozites which migrate to salivary glands to be inoculated into human
-
Malaria asexual cycle
- sporozoites:
- infective stage injected from mosquito
- circulates to liver and invades heptocytes
- exoerythrocytic forms:
- in liver, sporozoites -> schizonts -> merozoites
- merozoites circulate and invade erthyrocytes
- erthyrocytic forms:
- merozoites inside erythrocytes grow into ring form called trophozoites that absorb hemoglobin
- trophozoites become schizonts -> merozoites
- process called schizogeny
-
Malaria sexual cycle
- some merozoites differentiate into gametocytes - ingested by mosquito
- in the gut, gametocyte undergoes exflagellation releasing male gametes
- male gametes fertilize female gametes -> zygote
- zygote invades gut wall and develops into oocyst
- oocyst ruptures and releases sporozoites which migrate to salivary glands
-
Malaria pathogenesis
- asexual, erythrocytic parasites cause disease
- fever - basis not know
- anemia - rupture of infected blood cells during schizogeny and splenic sequestration of infected cells
- tissue hypoxia - from anemia and alterations in circulation
- P. falciparum causes more severe disease - increased merozoite released
-
Malaria immune pathogenesis
- hypergobulinemia - increase in number of globulin proteins
- antibody-mediated sequestration of platelets
- immune complex disease
- increase in the number of phagocytes
-
Malaria immunity
protective immune response eventually develops in people who survive multiple infections with malaria early in childhood - kills parasite, learn to limit the immune response
-
Malaria genetic protection
- individuals who lack Duffy protein on RBCs are more resistant to infection with P. vivax
- glucose-6-phosphate dehydrogenase deficiency
- pyruvate kinase deficiency
- sick cell disease
-
Malaria clinical
- general:
- fever with periodicity, chills, anemia, hepatosplenomegaly
- species specific:
- Pv and Po- fever and anemia can debilitate but death is rare, relapses occur
- Pm - mortality rare, no relapses, most often associate with immune complex disease
- Pf- lethal complications can develop
-
Malaria diagnosis
- clinical diagnosis
- microscopy of thick and thin blood smears
- rapid diagnostic tests
-
Malaria treatment
- antimalarials:
- quinine - from bark of cinchona tree
- chloroquine- prevents biocrystalization of toxic heme, resistance common
- mefloquine - synthetic analogue of quinine
- artemesinin - from bark of woodworm
- primaquine - targets livers stages, for latent infections
-
Malaria prevention
- reduction of contact between humans and mosquitoes
- mosquito control
- prophylactic antimalarials
- transgenic mosquitoes
- vaccines in development
-
bottlenecks in Malaria life cycle
- upon feeding, mosquito injects limited number of sporozoites
- limited number of gametocytes produced to be taken up by mosquito
-
Malaria vaccine development
- preerythrocytic-stage vaccine:
- prevent development of merozoites in humans
- induce immune response against sporozoites or infected hepatocytes
- prevent disease and transmission
- Sexual- or mosquito-stage vaccine:
- block transmission of parasites to mosquitoes by inducing immune response against sexual stages or the mosquito stages
- block transmission, does not prevent disease
-
Malaria vaccine candidate
- RTS,S Vaccine
- use 4 amino acid antigen from surface of sporozoite of Pf
- showed promising protective efficacy in trials
-
Dengue etiology
- genus Flavivirus
- +ssRNA genome
- 4 distint serotypes based on envelope protein
-
Dengue occurrence
- viruses originated in monkeys
- stayed localized until WWII caused transport of mosquitoes around the world
-
Dengue reservoir
- humans
- also circulates in non-human primates
-
Dengue transmission
- mosquitoes (daytime feeders)
- Aedes aegypti - not cold hardy, mostly breeds in artificial containers in urban environments
- Aedes albopictus - more cold adapted, more efficient at vertical transmission, more rural settings and natural containers
-
Dengue pathogenesis
- virus enters host with mosquito saliva during blood meal
- infects skin dendritic cells (Langerhans cells)
- cells move to lymph nodes, virus replicates, exits through budding
- can then infect other white blood cells
- immune response produces antibodies against the virus and T cells that kill infected cells
- infection with one serotype provides lifelong protection against that serotype
-
Dengue antibody dependent enhancement
non-neutralizing antibodies to the precursor membrane protein bind to immature virions and allow them to infect cells by binding to the Fc receptor
-
Dengue clinical
- undifferentiated fever
- classic dengue fever - acute febrile illness
- Dengue hemorrhagic fever - lasting longer
-
Dengue diagnosis
- clinical
- serology
- viral isolation in culture
- RT-PCR
-
Dengue treatment
supportive care
-
Dengue prevention
- mosquito control
- vaccines under development
-
Yellow Fever discovery
- Carlos Finlay proposed yellow fever might be transmitted by mosquitoes
- caused more deaths than military deaths
- Walter Reed confirmed
-
Yellow Fever etiology
- genus Flavivirus
- +ssRNA genome
- 4 genotypes
-
Yellow Fever reservoir
- humans
- in jungle, non-human parasites harbor - called sylvatic cycle
-
Yellow Fever transmission
- mosquitoes
- Aedes aegypti - breeds in containers
-
Yellow Fever pathogenesis
- virus replicates at mosquito bite and in local lymph nodes, spreads via bloodstream
- primary target organ is the liver
- immune response - neutralizing antibodies appear after 7 days, offer lifelong protection
-
Yellow Fever clinical
- asymptomatic
- nonspecific febrile illness
- life-threatening hemorrhagic fever:
- acute phase
- remission phase
- intoxication phase
-
Yellow Fever diagnosis
- serology
- histology of liver
- direct isolation in mosquito cell culture
- RT-PCR
-
Yellow Fever treatment
- no cure
- supportive treatment
- passive immunization, antivirals
- avoid aspirin due to anticoagulant effect
-
Yellow Fever prevention
- mosquito control
- international quarantine regulations
- vaccination
|
|